Search
Zhifei Biological's wholly-owned subsidiary, Zhifei Lvzhu, has successfully developed an independently crafted ACYW135 group meningococcal polysaccharide conjugate vaccine, also known as the quadrivalent meningococcal conjugate vaccine. The company has submitted an application for production registration, which has been favorably received by the National Medical Products Administration. Presently, China's market only hosts one similar vaccine. Upon approval, this vaccine is poised to complement Zhifei Biological's existing meningococcal vaccine portfolio, thereby bolstering its market competitiveness. Despite the lengthy development cycle, substantial investment, and inherent risks associated with pharmaceutical research and development, this acceptance does not foreseeably influence the company's immediate financial performance.
-
C114 Communication Network -
Communication Home
